News & Media

SK life science

Welcome to the news and information center for SK Life Science, Inc. (SKLSI), a CNS-focused pharmaceutical company

General business

Strategic alliance and partnership opportunities

Media inquiries and PR

Grant and investigator initiated proposals

Sponsorship requests

Medical information inquiries or report adverse events

SK life science at a glance

  • Headquarters location


  • R&D Begins


  • Parent Company

    SK life science is a subsidiary of SK Biopharmaceuticals, Co., Ltd., and both are part of the SK Group

  • Number of employees

    200+ EMPLOYEES

  • Disease Category Focus


  • Pipeline

    8 compounds under clinical development


SK life science Presents Long-Term Data of XCOPRI® (cenobamate tablets) CV in Adults with Partial-Onset Seizures at the American Epilepsy Society 2021 Annual Meeting

Full release

SK life science To Present Latest XCOPRI® (cenobamate tablets) CV Data at the American Epilepsy Society 2021 Annual Meeting

Full release

SK Biopharmaceuticals Enters Greater China Out-Licensing 6 Clinical Pipelines to CNS-Focused Biotech Ignis Therapeutics

Full release

Epilepsia Publishes Two Post-hoc Analyses from Long-Term Study of XCOPRI® (cenobamate tablets) CV

Full release

SK Life Science, Inc. Launches STEPS Toward Zero Movement to Educate, Inspire and Activate the Epilepsy Community

Full release

Long-Term Safety and Tolerability of XCOPRI® (cenobamate tablets) CV Published in Epilepsia

Full release

SK life science Reports Effectiveness Of Long-Term Use With Cenobamate

Full release

SK life science To Present Latest Cenobamate Data at the American Academy of Neurology 2021 Virtual Annual Meeting

Full release

ONTOZRY® (Cenobamate) Receives European Commission Approval for the Treatment of Drug-Resistant Focal-Onset Seizures in Adults

Full release

Cenobamate Receives Positive CHMP Opinion for Adjunctive Treatment of Focal-Onset (Partial-Onset) Seizures

Full release